3-(2-butyl-1H-imidazol-4-yl)propan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-butyl-1H-imidazol-4-yl)propan-1-ol
• 英文别名: 3-(2-butyl-1H-imidazol-5-yl)propan-1-ol
• 化学式: C₁₀H₁₈N₂O
• mdl: MFCD09927065
• 分子量: 182.266
• InChiKey: AXRDPLGSMRKETI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-butyl-1H-imidazol-4-yl)propan-1-ol 在 potassium carbonate 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 4'-(2-butyl-4-{3-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxy]propyl}imidazol-1-ylmethyl)biphenyl-2-carboxylic acid dipotassium salt
  参考文献：
  名称：

  Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor

  摘要：

  Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT(1)) receptor and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-gamma and to block AT(1) receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-gamma activating and AT(1) blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.08.082
• 作为产物：
  描述：

  2-丁基-1H-咪唑-4-甲醛 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.5h， 生成 3-(2-butyl-1H-imidazol-4-yl)propan-1-ol
  参考文献：
  名称：

  Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor

  摘要：

  Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT(1)) receptor and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-gamma and to block AT(1) receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-gamma activating and AT(1) blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.08.082

文献信息

• Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor
  作者：Maxime Meyer、Sébastien Foulquier、François Dupuis、Stéphane Flament、Linda Grimaud、Daniel Henrion、Isabelle Lartaud、Gérald Monard、Isabelle Grillier-Vuissoz、Michel Boisbrun

  DOI：10.1016/j.ejmech.2018.08.082

  日期：2018.10

  Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT(1)) receptor and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-gamma and to block AT(1) receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-gamma activating and AT(1) blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach. (C) 2018 Elsevier Masson SAS. All rights reserved.